Moneycontrol PRO

Sun Pharma: Traction in speciality likely to sustain

Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well

May 31, 2021 / 10:53 AM IST
Sun Pharma: Traction in speciality likely to sustain

Revlimid is a blockbuster blood cancer drug with sales of $12.1 billion for BMS in 2020.

PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook

India’s largest pharma company, Sun Pharma (CMP: Rs 670, Market Cap: Rs 160,695 crore), posted a decent growth in domestic formulations in the quarter gone by. However,  the improving outlook for global specialty business calls for attention. Sales of specialty products clocked $139 million (versus $148 million in Q3 FY21), sequentially weaker due to some pre-buying at the end of the last calendar year. However, compared to last year, sales were up 10 per cent. Key specialty products, particularly Ilumya...

  • PRO Panorama

    Moneycontrol Pro Panorama | Startups are feeling the cash squeeze

    Aug 10, 2022 / 05:30 PM IST

    In today’s edition of Moneycontrol Pro Panorama: Indian Hotels has more room to run, Marico is getting well oiled, huge trade deficit an eyesore, JD(U)'s love-hate feeling for NDA and more

    Read Now
  • PRO Weekender

    Moneycontrol Pro Weekender | Shaktikanta Das refuses to pivot 

    Aug 6, 2022 / 10:21 AM IST

    A look at the current macro readings is enough for the RBI governor not to budge and dilute his ‘withdrawal of accommodation’ stance

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers